FC

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, November 2, 2023
CAR, Kite Pharma, Malignancy, FC, International Conference on Nuclear Disarmament, Oslo, 2008, B-cell lymphoma, Safety, Research and development, American Society of Clinical Oncology, Conference, Chair, Society, Development, ASH, Risk, Allotransplantation, Follicular lymphoma, Annual general meeting, Kinetics, Cancer, University, ICML, H. Lee Moffitt Cancer Center & Research Institute, Immunotherapy, Therapy, MD Anderson Cancer Center, Investigator's brochure, ASCO, SAN, Pharmaceutical industry, Vaccine, Patient

“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.

Key Points: 
  • “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
  • Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
  • Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.

China Bispecific Antibodies Market and Clinical Pipeline Insight Report 2023: A $5 Billion Opportunity by 2028, 250 Pipeline Bispecific Antibodies, 50 Bispecific Antibodies Available for License - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Pharmaceutical, Health, Knowledge, Name, FDA, NMPA, BioNTech, Monoclonal antibody, Invention, PD-1, Organization, Research, Engineering, Growth, Antibody, Immunotherapy, Epitope, Chemistry, FC, Generic drug, Vaccine

The "China Bispecific Antibodies Market and Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Bispecific Antibodies Market and Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The continuously expanding bispecific antibodies market has also seen several research and clinical collaborations, as well as licensing and technology transfer deals pertaining to bispecific antibodies, in the last year, signifying the rapid speed at which bispecific antibodies are taking over the immunotherapy market in China.
  • The bispecific antibodies market is still in its nascent stage in China, with only few NMPA approved candidates of this drug class in the market.
  • China Bispecific Antibodies Market Opportunity: > USD 5 Billion
    China Bispecific Antibodies Clinical Pipeline By Company, Indication and Phase
    Clinical Insight On Bispecific Antibodies Clinical Pipeline: > 250 Bispecific Antibodies
    Indigenously Developed Bispecific Antibodies Available For Licensing: > 50 Bispecific Antibodies

FranklinCovey Launches Next Generation Courses, Leading at the Speed of Trust and Working at the Speed of Trust, to Meet the Challenges Organizations Are Facing Today

Retrieved on: 
Thursday, November 2, 2023
Technology, Consulting, Professional Services, Small Business, Software, Continuing, Training, Data Management, Education, Online, Former, Research, Asian option, NYSE, FC, Tax, Uncertainty avoidance, Behavior, Organization, AT&T, Creativity, Gallup, Learning, Growth, Essay, Business, True Corporation, Probability, Khouri, AT, Consultant, Culture, Credibility, Communication, Nursing, Sales, Online shopping, Tutoring, FranklinCovey, Trust

“Everything leaders and individual contributors say and do affects the level of trust in their team.

Key Points: 
  • “Everything leaders and individual contributors say and do affects the level of trust in their team.
  • Organizations with the highest levels of trust have 3.6 times more revenue growth than organizations with the lowest levels of trust.
  • Leaders discover evidence of high- and low- personal trust through the Speed of Trust Leader Assessment (a 360 instrument).
  • Discover evidence of high- and low trust among the team through the Speed of Trust Team Assessment.

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Retrieved on: 
Monday, November 6, 2023
HSR, ESMO, VHH, BioNTech, Inflammation, Hart–Scott–Rodino Antitrust Improvements Act, Immunoglobulin G, Tumor microenvironment, Safety, Patient, Toxicity, FC, Pharmaceutical industry

ZHUHAI, China, Nov. 6, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China. PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.

Key Points: 
  • PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.
  • The transaction is expected to close in Q4 2023, subject to customary closing conditions, including clearance under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act, and regulatory clearances.
  • PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations.
  • "Biotheus' innovative platform has the capability to expedite preclinical research, bolstering our impressive innovative pipeline of products with encouraging efficacy and safety including PM8002.

Franklin Covey Reports Strong Financial Results for Full Year Fiscal 2023 and Fourth Quarter

Retrieved on: 
Wednesday, November 1, 2023
Technology, Consulting, Professional Services, Small Business, Software, Continuing, Training, Data Management, Education, Consolidated, America the Beautiful Pass, Growth, Technical and Madrasah Education Division, NYSE, International, FC, Behavior, SG, EBITDA, Person, Organization, Walker, Telephone, International direct dialing, Herd, All Access Pass, Common, Travel, AAP, Finance, Investment, Rare-earth element, Video game, Security (finance), Bookkeeping, Cryptocurrency, Recycling, Adjustment

Paul Walker, President and Chief Executive Officer, commented, “We were really pleased with our results for the fourth quarter and full fiscal 2023 year.

Key Points: 
  • Paul Walker, President and Chief Executive Officer, commented, “We were really pleased with our results for the fourth quarter and full fiscal 2023 year.
  • The following is a summary of financial results for the fourth quarter of fiscal 2023:
    Net Sales: Consolidated sales for the quarter ended August 31, 2023, were $78.0 million compared with $78.8 million in the fourth quarter of fiscal 2022.
  • For the fourth quarter of fiscal 2023, Enterprise Division sales grew to $52.4 million compared with $52.2 million in fiscal 2022.
  • On Wednesday, November 1, 2023, at 5:00 p.m. Eastern (3:00 p.m. Mountain) Franklin Covey will host a conference call to review its fourth quarter and fiscal 2023 full-year financial results.

New Platform Brings Enterprise Software to Market as Fast as Consumer Tech

Retrieved on: 
Thursday, November 2, 2023
Enterprise software, CIO, Growth, Ideation, G2000, Risk, Centripetal force, Partnership, FC, Acceleration, Multimedia, Cryptocurrency, Risk management

Validation-at-scale approach, created by Fc Centripetal, revolutionizes enterprise software startup acceleration, expediting market entry for increased returns.

Key Points: 
  • Validation-at-scale approach, created by Fc Centripetal, revolutionizes enterprise software startup acceleration, expediting market entry for increased returns.
  • Integration of enterprise IT decision makers from the outset streamlines the path, reducing risk and accelerating growth.
  • The integration of enterprise IT decision makers from the outset streamlines the path, reducing risk and accelerating growth.
  • Meanwhile, CIOs and IT decision-makers harness Fc's transformative platform to improve their enterprise architectures and access innovative solutions, ultimately mitigating risk.

REPX and Visa Sign Global Agreement to Implement REPX Business Model Targeting Sports Clubs and Celebrities

Retrieved on: 
Wednesday, October 25, 2023
Fintech, Social media, Sport, FC, Rangers F.C., Visa, Co-branding, VISA, Music, Turin, Football, Movement, Esports, VAP, Payment card, Online shopping

London, United Kingdom--(Newsfile Corp. - October 25, 2023) - The Reputation Exchange PLC (REPX) and Visa, one of the world leaders in digital payments, have signed a global card agreement. This step will help REPX implement its business model and accelerate its strategic activity, and will better enable it to build business relationships in new territories around the world and develop digital banking solutions tailored to football and sports fans, as well as brands the fintech is working with to create innovative payment products.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - October 25, 2023) - The Reputation Exchange PLC (REPX) and Visa, one of the world leaders in digital payments, have signed a global card agreement.
  • This exciting relationship between REPX and Visa will continue to develop bringing new, innovative, engaging payment experiences to fans around the world.
  • REPX is a fintech revolutionising traditional banking by combining technology and the passion of billions of fans worldwide with social media.
  • "Thanks to this strategic global agreement with Visa," comments Antonio Matta, Executive Director of REPX, "Our innovative fintech will be better equipped to provide its core catchment area, i.e.

Brera Holdings Announces the Launch of its FENIX Trophy 2023-24 Edition First Kick-Off on October 24th Features Prague Raptors Hosting Venus Bucharest

Retrieved on: 
Tuesday, October 24, 2023
Venus, F.C. United of Manchester, K.S.K. Beveren, Brera, Exhibition, Czech Republic, Boldklubben Skjold, ESG, FC, Final four, 2018 Mongolian Premier League, Enfield Town F.C., Beveren, 1st Division, Fenix Trophy, Environment, Tournament, League, Mongolian, BBC Sport, Llantwit Major, 2016 Liberian First Division League, Hunting

The first match will be hosted by the Prague Raptors (Czech Republic), their third participation in the tournament and runners up in both previous editions, who will face newcomers Venus Bucharest (Romania).

Key Points: 
  • The first match will be hosted by the Prague Raptors (Czech Republic), their third participation in the tournament and runners up in both previous editions, who will face newcomers Venus Bucharest (Romania).
  • The defending champion BK Skjold  (Denmark) will debut on November 28th challenging Enfield Town FC (England) in London.
  • The FENIX Trophy combines the best features of great international football with the spirit of non-professional football.
  • Key matches from across Europe streamed live on the FENIX Trophy TV YouTube Channel are accompanied by values such as hospitality and sharing between the clubs.

FranklinCovey Named a Winner of a 2023 Training Magazine Network Choice Award for Outstanding Leadership Development Solutions, Products, and Training

Retrieved on: 
Wednesday, October 25, 2023
Human Resources, Other Communications, Publishing, Consulting, Thought Leadership, Communications, Business, Professional Services, Other Professional Services, L&D, Leadership development, Learning, Training, TMN, NYSE, FC, Management, FranklinCovey

FranklinCovey ( NYSE:FC ), one of the largest and most trusted leadership companies in the world, has been named by Training magazine as a winner of a 2023 Training Magazine Network Choice Award in a crowd-sourced vendor awards program that recognizes outstanding leadership development solutions, products, and training.

Key Points: 
  • FranklinCovey ( NYSE:FC ), one of the largest and most trusted leadership companies in the world, has been named by Training magazine as a winner of a 2023 Training Magazine Network Choice Award in a crowd-sourced vendor awards program that recognizes outstanding leadership development solutions, products, and training.
  • “We express our deepest thanks for this award to Training and its learning and development community members, many of whom are clients who voted on our behalf,” said Paul Walker , FranklinCovey CEO.
  • “We’re delighted our leadership development solutions, products, and training are received so exceptionally well by them.
  • We go beyond just skill development and aim to change paradigms and mind-sets of everyone inside an organization to generate collective behavior change at scale, leading to breakthrough results.”
    Training magazine Editor and Publisher Lorri Freifeld said, “Kudos to FranklinCovey as a 2023 Training Magazine Network winner in the category of Leadership Development .

Vagus nerve stimulation reduces inflammation in children with Inflammatory Bowel Disease, Feinstein Institutes study finds

Retrieved on: 
Wednesday, October 18, 2023
Research, Managed Care, General Health, Consumer, Medical Devices, Children, Science, Biotechnology, Neurology, Practice Management, Other Science, Health, Abdominal pain, Child, MRI, Medical research, Feinstein, Inflammation, Feinstein Institutes for Medical Research, Cohen, FC, Vagus nerve, Weatherall Institute of Molecular Medicine, Heart rate, Diarrhea, Human, Medicine, Prevalence, Vagus nerve stimulation, Incontinence, Diabetes, Rheumatoid arthritis, MBA, Electricity, TENS, Bleeding, GE Research, Ulcerative colitis, Multimedia, Northwell Health, Disease, Clinical trial, Nature Communications, Pulmonary hypertension, Neuroscience, Ear, Arthritis, IBD, Sickle Cell Anemia, a Molecular Disease, Credit, Molecular medicine, Brain, Cancer, Patient, Liver disease, Biomedical engineering, Bangladesh Technical Education Board, MS, Central nervous system, Lupus, Medical imaging, Pharmaceutical industry, Management, Gastroenterology, MD

View the full release here: https://www.businesswire.com/news/home/20231018401966/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018401966/en/
    The Feinstein Institutes for Medical Research’s Dr. Benjamin Sahn led the vagus nerve stimulation clinical trial.
  • Inflammation and the inflammatory reflex – the neuronal signaling between the brain and body – is an important immune response.
  • Previous research and functional MRI studies have mapped stimulation of the auricular branch of the vagus nerve to activate the same brain regions as implanted devices, confirming this nerve as a suitable non-invasive target to administer vagus nerve stimulation.
  • Also, Feinstein Institutes researchers, in collaboration with GE Research, published research that harnessed ultrasound technology to reduce inflammation in the body non-invasively.